GAITHERSBURG, Md., July 21,
2023 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ:
YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical
company dedicated to discovering, developing, manufacturing, and
delivering new generations of vaccines and therapeutic biologics
for infectious diseases and cancer, today announced that it
plans to release its financial results for the fiscal year ended
March 31, 2023 after the U.S. market
closes on Wednesday, July 26, 2023.
The Company's management will hold an earnings conference call
at 8:00 P.M. Eastern Time on Wednesday,
July 26, 2023 to discuss the financial results. Listeners
may access the call by dialing the following numbers:
United States Toll
Free:
|
1-888-346-8982
|
International:
|
1-412-902-4272
|
Mainland China Toll
Free:
|
4001-201203
|
Canada Toll
Free:
|
18556699657
|
Hong Kong:
|
852-301-84992
|
Upon dialing-in, participants should ask to be joined into
the YS Biopharma Co., Ltd. call.
The replay will be accessible through August 2,
2023 by dialing the following numbers:
United States Toll
Free:
|
1-877-344-7529
|
International:
|
1-412-317-0088
|
Canada Toll
Free:
|
855-669-9658
|
Access Code:
|
8524425
|
A live and archived webcast of the conference call will also be
available at the Company's investor relations website at
https://investor.ysbiopharm.com/.
About YS Biopharma
YS Biopharma is a global biopharmaceutical company
dedicated to discovering, developing, manufacturing, and delivering
new generations of vaccines and therapeutic biologics for
infectious diseases and cancer. It has developed a proprietary
PIKA® immunomodulating technology platform and a
new generation of preventive and therapeutic biologics targeting
Rabies, Coronavirus, Hepatitis B, Influenza, Shingles, and other
virus infections. YS Biopharma operates
in China, the United States, Singapore, and the
Philippines, and is led by a
management team that combines rich local expertise and global
experience in the biopharmaceutical industry. For more information,
please visit investor.ysbiopharm.com.
Investor Relations Contact
Robin Yang
Partner, ICR, LLC
Tel: +1 (212) 537-4035
Email: YSBiopharma.IR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ys-biopharma-to-report-financial-results-for-fiscal-year-2023-on-july-26-2023-301883129.html
SOURCE YS Biopharma Co., Ltd.